Optune Lua™ is the new FDA approved name for NovoTTF-100L™. All NovoTTF-100L materials will be updated shortly with the new name, Optune Lua. Thank you for your patience while we make these updates. Read the Press Release

Read the Press Release

Optune Lua

For the first time in over 15 years, there's
an FDA-approved treatment for mesothelioma

Optune Lua + chemotherapy is approved to
treat people with unresectable, locally advanced
or metastatic, malignant pleural mesothelioma

The majority of people who used Optune Lua + chemotherapy saw their mesothelioma shrink or stop growing

  • The only side effect of Optune Lua was skin irritation seen in 71% of patients (66% mild to moderate and 5% severe)
Learn more about study results for Optune Lua™ + chemo

A clinical study showed using Optune Lua + chemotherapy helped people with mesothelioma live longer

See the clinical data
24/7 support for you and your caregiver

24/7 support for you and your caregiver

Learn more about nCompass™
Downloadable Skin Care Guidelines, Understanding Optune Lua™, and nCompass™ support brochure

Resources
you can download

Download here
Learn about the number of patients who have been treated with TTFields to date

More than 10,000 people globally have started a cancer treatment that works the same way as Optune Lua. It is called Optune® and has been used since 2011 to treat a type of brain cancer called glioblastoma, also known as GBM.

The FDA first approved Optune to treat recurrent GBM in 2011, and newly diagnosed GBM in 2015.

Optune Lua for MPM is classified as a Humanitarian Use Device (HUD), approved under the Humanitarian Device Exemption (HDE) pathway.

Optune was approved under the Premarket Approval (PMA) Pathway.



Caution: Federal law restricts this device to sale by or on the order of a physician. Humanitarian Device. Authorized by Federal Law for use in the treatment of adult patients with unresectable, locally advanced or metastatic, malignant pleural mesothelioma concurrently with pemetrexed and platinum-based chemotherapy. The effectiveness of this device for this use has not been demonstrated.

Device carrying bag for everyday life

References: 1. Optune Lua. Instructions for Use for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019. 3. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta®). The Oncologist. 2004;9(5):482-488. 4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-2644. 5. Optune Lua. Patient Information and Operation Manual for Unresectable Malignant Pleural Mesothelioma. Novocure; 2019. 6. Summary of Safety and Effectiveness Data (SSED). US FDA Website. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100034s013b.pdf. Accessed April 9, 2019.

Next: Disease overview
Back to top
What is the Optune Lua™ System approved to treat?
jump to isi

The Optune Lua System is a wearable, portable, FDA-approved device indicated for…